BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, currently in Phase 3, dedicated to revolutionizing cancer treatment through its innovative cellular immunotherapies. Its flagship product, Bria-IMT, is currently undergoing a pivotal Phase 3 clinical trial for advanced breast cancer, where it's being evaluated in combination with an immune checkpoint inhibitor. Beyond this lead candidate, the company is also advancing the development of personalized, off-the-shelf treatments designed to combat breast, prostate, and various other forms of cancer. Furthermore, BriaCell maintains a strategic partnership with Incyte Corporation, focused on further evaluating Bria-IMT in combination therapies. The company's operations are headquartered in West Vancouver, Canada.